Melphalan HCl 50mg/vial; pwd for IV infusion after reconstitution and dilution. Melphalan is an alkylating agent with cytotoxic action that appears to be related to the extent of its interstrand ...

Melphalan 200 mg/m 2 vs melphalan 100 mg/m 2 in newly diagnosed myeloma patients: a prospective multicenter phase 3 study. Blood 115 , 1873–1879 (2010). Article CAS PubMed Google Scholar ...

Recent evidence suggests that patients with newly diagnosed multiple myeloma treated with high-dose melphalan therapy prior to undergoing autologous stem cell transplantation (ASCT) are more ...

The study enrolled 30 metastatic uveal melanoma patients with liver metastases who received the Hepzato Kit as either ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

A 75-year-old woman with rheumatoid arthritis and multiple myeloma was admitted to the hospital with abdominal pain. She had ...

Delcath Systems, Inc. announced the presentation of new subgroup analysis data from the phase 3 FOCUS trial of Hepzato Kit (m ...

A significant number of multiple myeloma patients may have an inherited but previously unrecognized risk of developing the ...

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced the presentation of new subgroup analysis data from the FOCUS Phase ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the ...

When my friend Lynn was instructed to produce a 24-hour urine collection for analysis, the materials were provided in a ...